Monday Aug 25
Belviq Sales Rise 2%
Sales of the anti-obesity pill Belviq from Arena Pharmaceuticals continued to buck the seasonality factor by bringing in a 2% increase in week over week sales according to industry tracker IMS Health.
Monday Aug 25
Biotech Hiring Surge: Trends To Watch; Industry Tips from Arena Pharmaceuticals, Inc.
August 25, 2014 By Josh Baxt , BioSpace.com Exclusive Story Everyone remembers the bad old days of 2009.
Fri Aug 15, 2014
FDA Data: Good News For One Anti-Obesity Company, Not So Good For Another
The FDA Adverse Events raw data for Q4 of 2013 have been released, and while the exact information relating to the nature of adverse events will take some time to make its way to the public, it is possible to search through the raw data to see the number of times that a particular drug comes up within the data.
Wed Aug 13, 2014
A Deeper Look At MannKind - Sanofi Deal And Valuation
The excitement of the new deal between MannKind and Sanofi has now been absorbed, and the street is now assessing how it feels the deal will impact MannKind.
Arena Pharmaceuticals Short Interest Down 2.2% in July
Shares of Arena Pharmaceuticals were the recipient of a significant decrease in short interest during the month of July.
Mon Aug 11, 2014
For Lexicon Pharmaceuticals, No News Remains Bad News
Lexicon updates investors on its second quarter results, but still has no partner to develop LX4211 in Type 2 diabetes.
Post-Earnings Review and Highlights - Arena Pharma
Investor-Edge.com has issued complimentary earnings coverage on Arena Pharmaceuticals Inc. as the company featured in the headlines on, per diluted share decline in net income per share in the second quarter of 2014.
Fri Aug 08, 2014
Arena's Belviq Bucks Seasonality With 3.6% Week Over Week Gain
Sales of the anti-obesity pill Belviq from Arena Pharmaceuticals continue to buck the seasonality of the weight loss sector with a 3.6% week over week gain.
Thu Aug 07, 2014
Arena Pharmaceuticals Receives Consensus Rating of "Hold" from Brokerages
Shares of Arena Pharmaceuticals have earned a consensus rating of "Hold" from the eight ratings firms that are currently covering the stock, Analyst Ratings News reports .
Orexigen Hits Expectations But That Is Not The Big News
Orexigen announced its Q2 financial results this morning and the loss of $0.21 cents came in line with expectations.
Mon Aug 04, 2014
One-Time Stock Sale Boosts Arena To Profit
Arena Pharmaceuticals beat the street by an impressive $0.14 per share. Some investors were thrilled with the news, but more experienced investors saw the quarter for what it was and removed the one-time event to look at this quarter from a business perspective.
Fri Aug 01, 2014
Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results
"Other recent notable achievements consist of advancing our internally discovered pipeline and lorcaserin life-cycle management programs, and establishing a marketing and supply agreement for BELVIQ in IMS Health estimates that approximately 110,000 prescriptions for BELVIQ were filled in the second quarter of 2014, representing growth of ... (more)
Thu Jul 31, 2014
Possible Delay In Orexigen Approval Process In Europe
Orexigen announced on July 30 that the company has received a List of Outstanding Issues in the form of a 180 day Letter from the Committee for Medical Products For Human Use regarding the anti-obesity drug Contrave.
Cramer's Lightning Round - 6 Biotech Picks
Arena Pharmaceuticals : "I'm not a fan of it. People got mad at me because of that, but the stock is down."
Wed Jul 30, 2014
Earnings Expected to Swing to Loss for Arena Pharmaceuticals
When Arena Pharmaceuticals reports its second quarter results on Friday, August 1, 2014, analysts are anticipating a drop into the red.
Tue Jul 29, 2014
Eisai Inc. And Arena Pharmaceuticals, Inc. Announce BELVIQ??...
Award is considered one of the biomedical industry's top accolades. It recognizes outstanding achievements in improving the human condition through the development of innovative therapies.